The role of chemotherapy in early-stage (stage I and II) resectable non-small cell lung cancer

Seminars in Radiation Oncology

Volumn 10, Issue 4, 2000, Pages 274-279

  Pisters, Katherine M W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BCG VACCINE; CAMPTOTHECIN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL DERIVATIVE; GEMCITABINE; HYDROXYUREA; LEVAMISOLE; LOMUSTINE; METALLOPROTEINASE INHIBITOR; METHOTREXATE; MITOMYCIN; PACLITAXEL; TAXANE DERIVATIVE; TEGAFUR; UFT; VINDESINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0033792464     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2000.9129     Document Type: Article

References (24)

1. Cancer statistics, 2000
2. Revisions in the international system for staging lung cancer
3. Incidence of local recurrence and second primary tumors in resected stage I lung cancer
4. Lung cancer classifications: The relationship of disease extent and cell type to survival in a clinical trial population
5. Retrospective and prospective tumor staging evaluating prognostic factors in operated bronchus carcinoma patients
6. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer
7. Bronchogenic carcinoma. Nitrogen mustard as a surgical adjuvant and factors influencing survival. University surgical adjuvant lung project
8. Experience of the Veterans Administration surgical adjuvant group
9. Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung
10. Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-2627,2) for radically resected bronchogenic carcinoma
11. Fifteen-year follow-up of all patients in a study of postoperative chemotherapy for bronchial carcinoma
12. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma
13. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I NSCLC
14. Adjuvant chemotherapy after radical surgery, for non-small cell lung cancer: A randomized study
15. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: An intergroup trial (E3590)
16. A randomized controlled trial of postoperative adjuvant chemotherapy in non-small cell lung cancer
17. A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study)
18. Adjuvant chemotherapy after complete resection in non-small cell lung cancer
19. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
20. Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public
21. Long term follow-up of patients enrolled in a randomized trial comparing perioperatire chemotherapy and surgery with surgery, alone in resectable stage IIIA non-small cell lung cancer
22. Preresectional chemotherapy in stage IIIA non-small cell lung cancer: A 7-year assessment of a randomized controlled trial
23. Induction chemotherapy prior to surgery for early stage lung cancer - A novel approach
24. Phase III trial of neo-adjuvant chemotherapy (NCT) in resectable stage I (except T1N0), II, IIIA non-small cell lung cancer (NSCLC): The French experience